ondansetron has been researched along with tapentadol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bannister, K; Dickenson, AH; Goncalves, L; Patel, R; Townson, L | 1 |
1 review(s) available for ondansetron and tapentadol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for ondansetron and tapentadol
| Article | Year |
|---|---|
Diffuse noxious inhibitory controls and nerve injury: restoring an imbalance between descending monoamine inhibitions and facilitations.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Biogenic Monoamines; Diffuse Noxious Inhibitory Control; Disease Models, Animal; Duloxetine Hydrochloride; Evoked Potentials; Male; Neurons; Ondansetron; Peripheral Nerve Injuries; Phenols; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin and Noradrenaline Reuptake Inhibitors; Serotonin Antagonists; Tapentadol; Time Factors; Yohimbine | 2015 |